Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00217178|
Recruitment Status : Unknown
Verified October 2004 by McMaster University.
Recruitment status was: Active, not recruiting
First Posted : September 22, 2005
Last Update Posted : September 22, 2005
1. To evaluate whether combined therapy with folic acid 2.5 mg/day, vitamin B6 50 mg/day and vitamin B12 1000 micrograms/day vs placebo reduces the rate of atherosclerosis progression, as evaluated by quantitative B-mode carotid ultrasound (US).
|Condition or disease||Intervention/treatment||Phase|
|Atherosclerosis Cardiovascular Disease||Drug: Vitamins: Folic acid, B6, B12||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||900 participants|
|Intervention Model:||Factorial Assignment|
|Official Title:||Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)|
|Study Start Date :||January 2000|
|Study Completion Date :||October 2005|
- The change over time (annualized progression slope) in the mean maximum IMT (the mean maximum IMT slope) defined as the average of the maximum IMT across the 12 preselected carotid arterial segments.
- The change over time (annualized progression slope) in the single maximum IMT amongst any of the same preselected carotid artery segments, i.e. the hemodynamically most important lesson.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00217178
|Hamilton Health Sciences Corp.|
|Hamilton, Ontario, Canada, L8L 2X2|
|Principal Investigator:||Eva M Lonn, MD MSc FRCPC FACC||McMaster University|